# Program 15: Cancer Cell Biology

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $39,686

## Abstract

Cancer Cell Biology Program
Project Summary / Abstract
The mission of the Cancer Cell Biology (CCB) Program is to facilitate basic cancer research and accelerate the
application of basic science discoveries in the clinic through a deep understanding of the cellular and molecular
factors that underlie tumor formation, progression, and metastasis. Program members develop and utilize a
wide variety of cutting-edge technologies to address fundamental problems in cancer cell biology with the goal
of clinical translation. These technologies include molecular, biochemical, cell-based, and in vivo approaches
aimed at better understanding basic mechanisms of tumor behavior and therapeutic vulnerabilities.
The Program’s 120 members (90 primary and 30 secondary) represent all seven DF/HCC institutions and 18
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $19.3 million in
direct costs from the NCI and $13.4 million from other sponsors. During the current funding period, primary
members of the CCB Program published 1,240 cancer-relevant papers. Of these, 23% were inter-institutional,
15% were intra-programmatic, and 36% were inter-programmatic collaborations between two or more DF/HCC
members.
For the next CCSG funding period, the Program has three Specific Aims: 1) Elucidate the pathophysiology of
cancer; 2) Develop and disseminate new technologies for cancer research; and 3) Foster synergy between
clinical translation and basic research. These Aims will be achieved through established CCSG channels that
enable meaningful and productive scientific interactions between CCB and the Cancer Center’s ten disease-
specific Programs, three Basic Science Programs, three Programs in classical population sciences, and two
unique Programs in cancer risk, prevention, and early detection (CaRPED) and Developmental Therapeutics.
Overall, the Program is deeply committed to training future generations of basic and translational scientists,
including those from underrepresented minority backgrounds, and to translating our members’ fundamental
laboratory findings into proof-of-concept testing in DF/HCC clinical trials.

## Key facts

- **NIH application ID:** 10768682
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** KORNELIA POLYAK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $39,686
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768682

## Citation

> US National Institutes of Health, RePORTER application 10768682, Program 15: Cancer Cell Biology (5P30CA006516-59). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768682. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*